Amcasertib
Small moleculeexperimental
Clinical trial activity
10 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01781455)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(-c4csc(-c5ccccc5)n4)cc32)c1C- Mol. weight
- 539.71 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707349 ↗
Also known as
- bbi503
- bbi503
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05784779 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2023 | 1Globe Biomedical Co., Ltd. |
| NCT02232620 | Phase 2 | Mar 13, 2017 | Boston Biomedical |
| NCT02232646 | Phase 2 | Jan 1, 2017 | Boston Biomedical |
| NCT02483247 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Boston Biomedical |
| NCT02432690 | Phase 2 | Jun 1, 2015 | Boston Biomedical |
| NCT02432326 | Phase 1 | Apr 1, 2015 | Boston Biomedical |
| NCT02354898 | Phase 1 | Mar 1, 2015 | Sumitomo Dainippon |
| NCT02232633 | Phase 2 | Feb 1, 2015 | Boston Biomedical |
| NCT02279719 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | Boston Biomedical |
| NCT01781455 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Boston Biomedical |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Biomedical | For profit | 8 | 8 | 2 | 2012 |
| 1Globe Biomedical Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Sumitomo Dainippon | For profit | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1